Login to Your Account



Other News To Note


Wednesday, January 23, 2013
Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., acquired Molecular Insight Pharmaceuticals Inc., of Cambridge, Mass. Under the terms of the all-stock transaction, Progenics exchanged about 4.5 million shares of its common stock (8.9 percent of the total outstanding post-transaction shares) for all of the outstanding shares of Molecular Insight, which will become a wholly owned subsidiary of Progenics.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription